176 related articles for article (PubMed ID: 32029905)
1. Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.
Whitt J; Hong WS; Telange RR; Lin CP; Bibb J; Beebe DJ; Chen H; Jaskula-Sztul R
Cancer Gene Ther; 2020 Dec; 27(12):898-909. PubMed ID: 32029905
[TBL] [Abstract][Full Text] [Related]
2. A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor-guided antibody-drug conjugate: Perspectives on clinical response?
Herring B; Whitt J; Aweda T; Ou J; Guenter R; Lapi S; Berry J; Chen H; Liu X; Rose JB; Jaskula-Sztul R
Surgery; 2020 Jan; 167(1):197-203. PubMed ID: 31543319
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of therapy effects by botulinum neurotoxin].
Alajbegović A; Alajbegović S; Resić H
Med Arh; 2008; 62(1):53-5. PubMed ID: 18543757
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells.
Aburjania Z; Whitt JD; Jang S; Nadkarni DH; Chen H; Rose JB; Velu SE; Jaskula-Sztul R
Molecules; 2020 Oct; 25(21):. PubMed ID: 33114525
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
6. Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.
Somnay YR; Dull BZ; Eide J; Jaskula-Sztul R; Chen H
Cancer Gene Ther; 2015 Oct; 22(10):496-505. PubMed ID: 26403073
[TBL] [Abstract][Full Text] [Related]
7. Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A.
Dolly JO; Lawrence GW
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S14-20. PubMed ID: 25042137
[TBL] [Abstract][Full Text] [Related]
8. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
[TBL] [Abstract][Full Text] [Related]
9. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
Schulte-Mattler WJ
CNS Drugs; 2008; 22(9):725-38. PubMed ID: 18698873
[TBL] [Abstract][Full Text] [Related]
10. Botulinum neurotoxin A for chronic migraine headaches: does it work and how?
Cairns BE; Gazerani P
Pain Manag; 2014; 4(6):377-80. PubMed ID: 25494688
[No Abstract] [Full Text] [Related]
11. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
13. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system.
Mazzocchio R; Caleo M
Neuroscientist; 2015 Feb; 21(1):44-61. PubMed ID: 24576870
[TBL] [Abstract][Full Text] [Related]
14. Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.
Bandala C; Cortés-Algara AL; Mejía-Barradas CM; Ilizaliturri-Flores I; Dominguez-Rubio R; Bazán-Méndez CI; Floriano-Sánchez E; Luna-Arias JP; Anaya-Ruiz M; Lara-Padilla E
Int J Clin Exp Pathol; 2015; 8(7):8411-8. PubMed ID: 26339411
[TBL] [Abstract][Full Text] [Related]
15. Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth.
Cunningham D; Parajuli KR; Zhang C; Wang G; Mei J; Zhang Q; Liu S; You Z
Prostate; 2016 Nov; 76(15):1420-30. PubMed ID: 27325602
[TBL] [Abstract][Full Text] [Related]
16. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F.
Fu Z; Chen C; Barbieri JT; Kim JJ; Baldwin MR
Biochemistry; 2009 Jun; 48(24):5631-41. PubMed ID: 19476346
[TBL] [Abstract][Full Text] [Related]
17. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.
Buckel L; Savariar EN; Crisp JL; Jones KA; Hicks AM; Scanderbeg DJ; Nguyen QT; Sicklick JK; Lowy AM; Tsien RY; Advani SJ
Cancer Res; 2015 Apr; 75(7):1376-1387. PubMed ID: 25681274
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
19. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
[TBL] [Abstract][Full Text] [Related]
20. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
